ADDRESSING THE CAUSE OF ALZHEIMER'S AND PARKINSON'S
RATHER THAN THERAPIES TO TREAT THE SYMPTOMS
ProteoTech is one of a few companies at the forefront of developing disease-modifying small molecule compounds targeted at inhibiting the formation, aggregation and persistence of toxic amyloid deposits.
Our strategy has always been to develop therapeutics that address the initial cause and progression of amyloid diseases rather than taking the approach of current treatments available that primarily address symptoms in patients afflicted with these diseases.
ProteoTech has been successful in discovering three proprietary classes of compounds for therapeutic use that inhibit and disrupt the amyloid protein accumulation process. These classes of compounds include:
- Small molecule compounds, and small peptides
The Company believes that specific and newly identified compounds within these classes will be successful in preventing the progression of amyloid diseases.
All of the Company's technologies are protected through numerous United States and International patents and patent filings. ProteoTech's patent portfolio continues to grow rapidly with exciting new discoveries involving treatment, diagnostic and platform screening technologies which enables it to achieve ongoing rapid therapeutic development.